Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

5.43USD
1:40pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.43
Open
$5.40
Day's High
$5.43
Day's Low
$5.30
Volume
59,179
Avg. Vol
133,128
52-wk High
$7.30
52-wk Low
$1.86

Chart for

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.09
Market Cap(Mil.): $272.46
Shares Outstanding(Mil.): 50.18
Dividend: --
Yield (%): --

Financials

  AMRS.OQ Industry Sector
P/E (TTM): -- 32.89 25.08
EPS (TTM): -2.64 -- --
ROI: -- 8.58 8.44
ROE: -- 11.52 11.39

BRIEF-Temasek Holdings Reports 8.9 Pct Stake In Amyris Inc

* TEMASEK HOLDINGS (PRIVATE) LIMITED REPORTS 8.9 PERCENT STAKE IN AMYRIS INC AS OF MAY 22, 2018 - SEC FILING

May 23 2018

BRIEF-Amyris Says Novvi LLC and Chevron Entered Agreement

* AMYRIS SUSTAINABLE LUBRICANTS JOINT VENTURE COMPANY, NOVVI, AND CHEVRON ENTER AGREEMENT TO DEVELOP AND BRING TO MARKET NEW RENEWABLE BASE OIL TECHNOLOGIES

May 18 2018

BRIEF-Amyris Inc Files For Non-Timely 10-Q - SEC Filing

* AMYRIS INC FILES FOR NON-TIMELY 10-Q - SEC FILING Source text: (https://bit.ly/2wL2c8m) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 16 2018

BRIEF-Amyris Q1 GAAP Loss Per Share $1.79

* AMYRIS CONTINUES STRONG MOMENTUM AND EXECUTION WITH 77% REVENUE GROWTH AND EXCEEDS GROSS MARGIN TARGET

May 14 2018

BRIEF-Amyris Inc Files For Non-Timely 10-K With U.S. SEC

* AMYRIS INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC Source text: (https://bit.ly/2H66fh4) Further company coverage:

Apr 02 2018

BRIEF-Amyris Reports Q4 Gaap Loss Per Share $0.17

* AMYRIS REPORTS ANOTHER STRONG QUARTER WITH SOLID OPERATING PERFORMANCE AND 2017 REVENUE OF $143.4 MILLION UP 113% OVER 2016

Mar 15 2018

Earnings vs. Estimates